VASCULAR BIOGENICS IS-,01 WKN: A119YE ISIN: IL0011327454 Kürzel: 0VB Forum: Aktien Thema: Hauptdiskussion

Da geht noch was ...

Niemand investiert?

Was meint der ihr? Überlege zu verkaufen? Laut Chart gerade eine schöner Stand? 23 Prozent plus bei mir.

https://clinicaltrials.gov/ct2/results?cond=&term=vascular+Biogenics&cntry=&state=&city=&dist= 381 gelistete Patente https://patentscope.wipo.int/search/en/result.jsf?_vid=P20-K4D3VG-22927

The VBLT Opportunity Three novel platform technologies, with innovative mechanisms of action and strong IP • Lead candidate VB-111 in a Phase 3 potential-registration study for ovarian cancer • Final Phase 2 results in ovarian cancer were presented at ASCO 2019 • Phase 3 Interim analysis data expected 1Q 2020 • Two new Phase 2 investigator/NCI-sponsored studies expected to start soon • Potential across multiple solid tumors • In house commercial-scale gene therapy GMP manufacturing facility (20,000 sq.ft.) • Strategic deal on VB-201 for veterinary use, with potential of €50M payments to VBL • Two new antibody programs, in inflammation & oncology, advanced towards IND filing • Cash position secured for about 2 years, clear capital focus, no debt

Katalysatoren in Q1: - Launch of NCI-sponsored study of VB-111 in combination with checkpoint inhibitor in colon cancer - Launch of investigator-sponsored randomized controlled study of VB-111 in rGBM - OVAL study Interim analysis Katalysator in H1 - Pre IND submission MOSPD2 Inflammation program Katalysator Q4 - OVAL study second interim data Katalysator EOY - Preliminary Readout of VB-111 trial in colon cancer

VB-111 Development Program To Include 3 Clinical Trials in 2020 Our OVAL potential-registration study in ovarian cancer is recruiting patients in the US + Israel • Interim analysis expected 1Q 2020, will include CA-125 analysis for efficacy Investigator-initiated randomized controlled Phase 2 study in rGBM: • Launch expected 1Q 2020 • Readout expected 1H 2021 NCI-sponsored study of VB-111 in combination with a checkpoint inhibitor in GI tumors: • Launch expected 1Q 2020 • Preliminary readout expected YE 2020

MARKET CAP 41,622,108$ SHARES 35,881,128 Cash: 40,6Mio$ Burn: 1,3Mio$/Monat Ausreichend für 29 Monate (Anfang 2022) Stand 30.9.2019

🖐 VB-111 Recurrent platinum resistant ovarian cancer Phase 3 interim data due 1Q 2020